Effects of @entity1091 on XXXX metabolism in vivo.

@entity4485 @entity410 @entity8580 @entity1508 @entity7425 @entity4357 @entity19 @entity2134 @entity70872 @entity1076 @entity35 @entity1091 @entity4113 @entity11046 @entity13521
All of the known pathways for metabolizing the phospholipase C (EC 3.1.4.10) products of @entity7425 metabolism eventually lead to @entity70872 and products that are hydrolyzed by @entity8580 1-phosphatase (EC 3.1.3.25). That enzyme is inhibited by @entity1091 (Ki about 1 mM). In animals treated with @entity4113 , elevations of @entity11046 (1-IP) occur in brain that appear to result from endogenous neural activity for they are diminished by the anesthetics @entity1508 and @entity4485 . @entity1091 is thus a useful tool for assessing endogenous in vivo cerebral @entity7425 metabolism. The 1-IP elevation is also useful for revealing in vivo central nervous system (CNS) receptor activity that is stimulated by endogenous or exogenous processes such as the effects of centrally acting drugs and of @entity410 . Stimulation of the CNS in the presence of @entity1091 causes @entity8580 to be sequestered in 1-IP in proportion to the amount of stimulation. Thus if the @entity8580 level falls sufficiently resynthesis of the @entity4357 may be compromised and receptor response to stimuli may be reduced. Evidence for such an occurrence would support the theory that this is one mechanism by which @entity1091 acts in the therapy of @entity13521 . We extended our efforts to identify such a lowering of @entity7425 levels to @entity19 where cerebral metabolism can be halted more rapidly than in @entity35 . However, the only change detected was a small elevation in @entity1076 . We were successful, however, in causing all of the @entity4357 to be reduced in @entity35 cerebral cortex by @entity2134 stimulation after @entity1091 treatment, a procedure that causes @entity410 . The same procedure causes the largest reduction in cortical @entity8580 levels that we have observed, and thus may represent the point where the @entity8580 decrement is sufficient to interfere with resynthesis of the lipids.
